Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias.
Journal Information
Full Title: Leukemia
Abbreviation: Leukemia
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Competing interests EN reports research funding from Janssen during the conduct of the study. Other authors declare no competing interests."
"The study was funded by Janssen (Russia). The study was funded by Janssen who also provided study drug and had the option to comment on presentation. The investigators are independent data owners with final decision for content reporting in the article and unrestricted publication rights."
"Power and sample size were calculated using IBM SPSS SamplePower version 3.0.1. All other analyses were done with Prism 9 software, Version 9.2.0 (283). The study is registered with ClinicalTrials.gov, number NCT01582776, and is ongoing but closed to accrual."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025